Dianthus Therapeutics DNTH Income Statement
| FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|
| $6.24M— | —— | —— | ||
| $87.9M+168% | $32.84M-27.3% | $45.2M-3.4% | ||
| $24.99M+37.6% | $18.16M+0.8% | $18.01M-35.5% | ||
| $108.1M+112% | $51M-19.3% | $63.21M-15.4% | ||
| -$101.86M-111% | -$48.17M+20.8% | -$60.86M+18.5% | ||
| -1,633.7%— | —— | —— | ||
| $16.9M+266% | $4.62M— | —— | ||
| -$84.97M-95.1% | -$43.56M-53.0% | -$28.48M+60.0% | ||
| -1,362.8%— | —— | —— | ||
| -$2.61— | —— | -$21.15-1,527% | ||
| -$101.77M-113% | -$47.7M+19.1% | -$58.94M+18.9% | ||
| -1,632.2%— | —— | —— | ||
| -$101.86M-111% | -$48.17M+20.8% | -$60.86M+18.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's income statement data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.